last authored:
last reviewed:
Commonest lymphoma involving H&N= diffuse large B cell lymphoma (non-Hodgkins).
Typical presentation: cervical lymphadenopathy ± “B” symptoms. May also get unilateral
enlargement of Waldeyer’s ring (adenoid, palatine tonsil, tongue base tonsil)
incidence increases with age
a simple case introducing clincial presentation and calling for a differential diagnosis to get students thinking.
Malignant cell is typically a B lymphocyte, but may be T lymphocyte or NK cell.
B cell: precursor
mature
T cell
precursor
mature:
non-Hodgkin's lymphoma typically resents with painless lymphadenopathy
Nodal involvment may not follow orderly anatomic progression.
Examination for lymphadenopathy should be done as follows:
Lymph nodes chains exist as follows:
HEENT: occipital, posterior auricular, pre-auricular, tonsillar, submandibular, sub-mental, anterior/posterior cervical, supra- or infraclavicular
Axillary: pectoral, medial/posterior axillary, lateral
Hepato/splenomegaly
Inguinal: horizontal/vertical chains
Histology important in predicting progression and response to treatment.
FNA may point in right direction, but require LN architecture for staging, so
do excisional LN biopsy (send fresh for “lymphoma protocol”) or core needle biopsy.
Staging CT: H&N, chest, abdo, pelvis
Hematology may do bone marrow bx, gallium scan or serum protein electrophoresis
The differential includes:
The Ann Arbor staging is one of the more popular methods.
Stage I: cancer is in one region, with one lymph node and surrounding area. B symptoms may or may not be present.
Stage II: cancer is in two regions, both on the same side of the diaphragm.
Stage III: cancer is on both sides of the diaphragm.
Stage IV: cancer is disseminated, involving one or more extra-lymphatic organs (liver, bone marrow, or liver)
Watch and wait for many folks
oral or IV chemo, radiation
anti-CD20 may be used; can be coupled to radioisotope
Prognostic points include:
5 year survival:
0-1: 73%
2: 51%
3: 43%
4-5: 26%
Natural history:
indolent: years
aggressive: months
leukemia-like: weeks
authors:
reviewers: